中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2015年
1期
44-46
,共3页
糖尿病周围神经病变%木丹颗粒%联合治疗%疗效
糖尿病週圍神經病變%木丹顆粒%聯閤治療%療效
당뇨병주위신경병변%목단과립%연합치료%료효
Diabetic peripheral neuropathy%Mudan particles%Combination therapy%Efficacy
目的：观察木丹颗粒联合贝前列素钠、依帕司他治疗糖尿病周围神经病变的临床疗效及安全性。方法：将152例糖尿病周围神经病变患者，以随机数字表法分为2组各76例。对照组患者口服贝前列素钠40μg、1日3次＋依帕司他50 mg、1日3次，治疗组患者在对照组的基础上加用木丹颗粒7g、1日3次、口服。2组均以3周为1个疗程，观察治疗前、后2组患者的临床症状及肌电图改善情况。结果：治疗组、对照组患者总有效率分别为93.4％（71／76）、78.9％（60／76），差异有统计学意义（P＜0.05）。治疗后，2组患者正中神经和腓总神经的运动神经传导速度和感觉神经传导速度较治疗前均有明显改善，差异有统计学意义（ P＜0.05）；且治疗组较对照组改善更明显，差异有统计学意义（P＜0.01）。2组患者均未见明显的不良反应。结论：木丹颗粒联合贝前列素钠、依帕司他治疗糖尿病周围神经病变的疗效优于贝前列素钠、依帕司他联合治疗，且无明显不良反应。
目的：觀察木丹顆粒聯閤貝前列素鈉、依帕司他治療糖尿病週圍神經病變的臨床療效及安全性。方法：將152例糖尿病週圍神經病變患者，以隨機數字錶法分為2組各76例。對照組患者口服貝前列素鈉40μg、1日3次＋依帕司他50 mg、1日3次，治療組患者在對照組的基礎上加用木丹顆粒7g、1日3次、口服。2組均以3週為1箇療程，觀察治療前、後2組患者的臨床癥狀及肌電圖改善情況。結果：治療組、對照組患者總有效率分彆為93.4％（71／76）、78.9％（60／76），差異有統計學意義（P＜0.05）。治療後，2組患者正中神經和腓總神經的運動神經傳導速度和感覺神經傳導速度較治療前均有明顯改善，差異有統計學意義（ P＜0.05）；且治療組較對照組改善更明顯，差異有統計學意義（P＜0.01）。2組患者均未見明顯的不良反應。結論：木丹顆粒聯閤貝前列素鈉、依帕司他治療糖尿病週圍神經病變的療效優于貝前列素鈉、依帕司他聯閤治療，且無明顯不良反應。
목적：관찰목단과립연합패전렬소납、의파사타치료당뇨병주위신경병변적림상료효급안전성。방법：장152례당뇨병주위신경병변환자，이수궤수자표법분위2조각76례。대조조환자구복패전렬소납40μg、1일3차＋의파사타50 mg、1일3차，치료조환자재대조조적기출상가용목단과립7g、1일3차、구복。2조균이3주위1개료정，관찰치료전、후2조환자적림상증상급기전도개선정황。결과：치료조、대조조환자총유효솔분별위93.4％（71／76）、78.9％（60／76），차이유통계학의의（P＜0.05）。치료후，2조환자정중신경화비총신경적운동신경전도속도화감각신경전도속도교치료전균유명현개선，차이유통계학의의（ P＜0.05）；차치료조교대조조개선경명현，차이유통계학의의（P＜0.01）。2조환자균미견명현적불량반응。결론：목단과립연합패전렬소납、의파사타치료당뇨병주위신경병변적료효우우패전렬소납、의파사타연합치료，차무명현불량반응。
OBJECTIVE:To evaluate the clinical efficacy and safety of Mudan particles plus beraprost and epalrestat for diabetic peripheral neuropathy .METHODS: 152 patients with diabetic peripheral neuropathy were randomly divided into two groups of 76 cases each .The patients in the control group were orally administered with beraprost(40 μg) t.i.d plus epalrestat (50 mg) t.i.d alone, while the patients in the treatment group were orally administered with add-on Mudan particles (7 g) t.i.d.After treatment of 3 weeks ( one course of treatment ), the improvement in clinical symptoms and EMG in the two groups were evaluated .RESULTS:The total effective rates in the treatment group and the control group were 93.4%(71/76) and 78.9%(60/76), and the differences between the two groups were statistically significant ( P <0.05 ) .After treatment, the motor nerve conduction velocity and the sensory nerve conduction velocity of the median nerve and the common peroneal nerve in both groups were significantly improved compared with before treatment ( P<0.05 ) , with the treatment group showing better improvement than in the control group ( P <0.01 ) .No significant adverse reactions were noted in two groups .CONCLUSIONS: Mudan particles added to beraprost and epalrestat is as safe as beraprost plus epalrestat alone yet the former is more effective than the latter in treating diabetic peripheral neuropathy .
